Consecutive, multimodal therapy of cancer: selective biological initiation (OK-432), cytoplasmic and nuclear damage (FT-207 and cyclophosphamide), inhibition of repair (bleomycin), and activation of cleansing and surveillance mechanisms.
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001688:Biological Products / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage / Q000494:pharmacology; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000494:pharmacology; D003593:Cytoplasm / Q000187:drug effects; D004260:DNA Repair / Q000187:drug effects; D004273:DNA, Neoplasm / Q000378:metabolism; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D008297:Male; D009374:Neoplasms, Experimental / Q000276:immunology / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D010844:Picibanil / Q000627:therapeutic use*; D051381:Rats; D005641:Tegafur / Q000008:administration & dosage
D000970:Antineoplastic Agents; D001688:Biological Products; D004273:DNA, Neoplasm; D001761:Bleomycin; D005641:Tegafur; D010844:Picibanil; D003520:Cyclophosphamide